KZA Media Thread, page-1395

Thank you onesurfed, now a better understanding of GBM from this publication using animal studies using gene analysis.
"In our animal glioblastoma models, treatment with drugs targeting PI3Kγ consistently resulted in impressively durable responses to chemotherapy,"

The invitational GBM AGILE pivitol registration study arm for paxalisib in humans, should show similar results as published in phases 1 and 2 from both Genentech and Kazia trials.

We have previously discussed the ability of paxalisib to inhibit (deactivation) of all 4 isoforms of the PI3K protein.
"The key to curing this cellular "Stockholm syndrome" and possibly glioblastoma lies in a protein called phosphoinositide-3-kinase gamma isoform (PI3Kγ). Activation of this protein turns microglia and macrophages from immune cells that police cancer growth into hostage cells that promote cancer growth. Varner has studied this process for many years and pioneered drugs that restore the anti-tumor activities of microglia and macrophages".

Looking forward to the first interim data release for GBM AGILE, and management's early response to the FDA.

Regards.